IV iron sucrose for cancer and/or chemotherapy-induced anemia in patients treated with erythropoiesisstimulating agents

Community Oncology

Volumn 8, Issue 6, 2011, Pages 270-278

  Anthony, Lowell B ^a   Gabrail, Nashat Y ^b   Ghazal, Hassan ^c   Woytowitz, Donald V ^d   Flam, Marshall S ^e   Drelichman, Anibal ^f   Loesch, David M ^g   Niforos, Demi A ^h   Mangione, Antoinette ⁱ  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Nashat Cancer Center   (United States)

^c Kentucky Cancer Clinic   (United States)

^d Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^e Hematology/Oncology   (United States)

^f Newland Medical Associates   (United States)

^g Oncol/Hematology Associates Inc   (United States)

^h AAI Pharma Inc   (United States)

ⁱ DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; ANEMIA; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; BACKACHE; CANCER THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STROKE; THORAX PAIN; TREATMENT DURATION; TREATMENT PLANNING; VOMITING;

EID: 80052688881     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(12)70022-0     Document Type: Article

References (38)

1. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol 2006;77:378-386.
2. Groopman JE, Itri LM. Chemotherapyinduced anemia in adults: incidence and treat-ment. J Natl Cancer Inst 1999;91:1616-1634.
3. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
4. Williams B, Tannous R, Gupta S, et al. Chemotherapy-induced anemia in geriatric patients with non-Hodgkin's lymphoma. Consultant Pharmacist 2002;17:131-140.
5. Miller CB, Jones RJ, Piantadosi S, Abe-Loff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-1692.
6. NCCN Clinical Practice Guidelines in Oncology: Cancerand Chemotherapy-Induced Anemia, Version 2.2011. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf. Accessed June 16, 2011.
7. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010;116:4045-4059.
8. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
9. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
10. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
11. Drüeke TB, Bárány P, Cazzola M, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997;48:1-8.
12. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-46.
13. Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846-2856.
14. Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic re-sponse to darbepo etin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97-105.
15. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007;369:1502-1504.
16. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythro-poietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.
17. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
18. Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004;66:1193-1198.
19. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999;33:464-470.
20. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
21. Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-632.
22. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
23. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-1625.
24. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001;38:988-991.
25. Lerchenmueller C, Husseini F, Gaede B, Mossman T, Suto T, Vanderbroek A. Intravenous (IV) iron supplementation in patients with chemotherapy-induced anemia (CIA) receiving darbepoetin alfa every 3 weeks (q3w): iron parameters in a randomized controlled trial. Blood 2006;108:1552.
26. Pinter T, Mossman T, Suto T, Vansteen-Kiste J. Effects of intravenous iron supplementation on responses to every-3-week darbepoetin alfa by baseline hemoglobin in patients with chemotherapy-induced anemia. J Clin Oncol 2007;25(18S):9106.
27. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001;84(suppl 1):17-23.
28. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 2001;19:2865-2874.
29. Henry DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275-278.
30. Ganz T. Hepcidin-a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract ClinHaematol 2005;18:171-182.
31. Ganz T. Hepcidin-a peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol 2006;306:183-198.
32. Viatte L, Nicolas G, Lou DQ, et al. Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood 2006;107:2952-2958.
33. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002;100:3776-3781.
34. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006;108:3204-3209.
35. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010;85:650-654.
36. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dialysis Transplant 2005;20:1443-1449.
37. Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005;46:283-289.
38. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534.